Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2, two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both sporadic and familiar. PARP is a family of enzymes involved in the base excision repair (BER) system. The introduction of inhibitors of PARP in patients with BRCA-mutated ovarian cancer is correlated with the concept of synthetic lethality. Among the PARP inhibitors introduced in clinical practice, niraparib showed interesting results in a phase III trial in the setting of maintenance treatment in ovarian cancer, after platinum-based chemotherapy. Interestingly, was niraparib showed to be efficacious not only in BRCA-mutated patients, but also in patients with other alterations of the homologous recombination (HR) system and in patients with unknown alterations. These results position niraparib as the first PARP-inhibitor with clinically and statistically significant results also in patients with no alterations in BRCA 1/2 and other genes involved in the DNA repair system. Even if the results are potentially practice-changing, the action of niraparib must be further studied and deepened.
Niraparib in ovarian cancer. results to date and clinical potential / Caruso, Davide; Papa, Anselmo; Tomao, Silverio; Vici, Patrizia; BENEDETTI PANICI, Pierluigi; Tomao, Federica. - In: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. - ISSN 1758-8340. - 9:9(2017), pp. 579-588. [10.1177/1758834017718775]
Niraparib in ovarian cancer. results to date and clinical potential
CARUSO, DAVIDEPrimo
;PAPA, ANSELMO
Secondo
;TOMAO, SILVERIO;BENEDETTI PANICI, PIERLUIGIPenultimo
;TOMAO, FEDERICAUltimo
2017
Abstract
Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2, two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both sporadic and familiar. PARP is a family of enzymes involved in the base excision repair (BER) system. The introduction of inhibitors of PARP in patients with BRCA-mutated ovarian cancer is correlated with the concept of synthetic lethality. Among the PARP inhibitors introduced in clinical practice, niraparib showed interesting results in a phase III trial in the setting of maintenance treatment in ovarian cancer, after platinum-based chemotherapy. Interestingly, was niraparib showed to be efficacious not only in BRCA-mutated patients, but also in patients with other alterations of the homologous recombination (HR) system and in patients with unknown alterations. These results position niraparib as the first PARP-inhibitor with clinically and statistically significant results also in patients with no alterations in BRCA 1/2 and other genes involved in the DNA repair system. Even if the results are potentially practice-changing, the action of niraparib must be further studied and deepened.File | Dimensione | Formato | |
---|---|---|---|
Caruso_Niraparib-ovarian-cancer_2017.pdf
accesso aperto
Note: https://journals.sagepub.com/doi/full/10.1177/1758834017718775
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
520.46 kB
Formato
Adobe PDF
|
520.46 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.